Clinical trial

GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer

NCT07554859

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention ArmA:GFH375 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Arm B:GFH375 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Arm C:GFH375 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-05-20

PhasePHASE2

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)unresolved

Interventions

ArmA:GFH375DRUG

Arm B:GFH375DRUG

Arm C:GFH375DRUG

Sponsors & collaborators

Genfleet Therapeutics (Shanghai) Inc.lead sponsor

Mapped research locations

GuangzhouGuangdong, China2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07554859 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.